HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases.

Abstract
Rare mutations in the gene encoding for tau (MAPT, microtubule-associated protein tau) cause frontotemporal dementia-spectrum (FTD-s) disorders, including FTD, progressive supranuclear palsy (PSP) and corticobasal syndrome, and a common extended haplotype spanning across the MAPT locus is associated with increased risk of PSP and Parkinson's disease. We identified a rare tau variant (p.A152T) in a patient with a clinical diagnosis of PSP and assessed its frequency in multiple independent series of patients with neurodegenerative conditions and controls, in a total of 15 369 subjects. Tau p.A152T significantly increases the risk for both FTD-s (n = 2139, OR = 3.0, CI: 1.6-5.6, P = 0.0005) and Alzheimer's disease (AD) (n = 3345, OR = 2.3, CI: 1.3-4.2, P = 0.004) compared with 9047 controls. Functionally, p.A152T (i) decreases the binding of tau to microtubules and therefore promotes microtubule assembly less efficiently; and (ii) reduces the tendency to form abnormal fibers. However, there is a pronounced increase in the formation of tau oligomers. Importantly, these findings suggest that other regions of the tau protein may be crucial in regulating normal function, as the p.A152 residue is distal to the domains considered responsible for microtubule interactions or aggregation. These data provide both the first genetic evidence and functional studies supporting the role of MAPT p.A152T as a rare risk factor for both FTD-s and AD and the concept that rare variants can increase the risk for relatively common, complex neurodegenerative diseases, but since no clear significance threshold for rare genetic variation has been established, some caution is warranted until the findings are further replicated.
AuthorsGiovanni Coppola, Subashchandrabose Chinnathambi, Jason JiYong Lee, Beth A Dombroski, Matt C Baker, Alexandra I Soto-Ortolaza, Suzee E Lee, Eric Klein, Alden Y Huang, Renee Sears, Jessica R Lane, Anna M Karydas, Robert O Kenet, Jacek Biernat, Li-San Wang, Carl W Cotman, Charles S Decarli, Allan I Levey, John M Ringman, Mario F Mendez, Helena C Chui, Isabelle Le Ber, Alexis Brice, Michelle K Lupton, Elisavet Preza, Simon Lovestone, John Powell, Neill Graff-Radford, Ronald C Petersen, Bradley F Boeve, Carol F Lippa, Eileen H Bigio, Ian Mackenzie, Elizabeth Finger, Andrew Kertesz, Richard J Caselli, Marla Gearing, Jorge L Juncos, Bernardino Ghetti, Salvatore Spina, Yvette M Bordelon, Wallace W Tourtellotte, Matthew P Frosch, Jean Paul G Vonsattel, Chris Zarow, Thomas G Beach, Roger L Albin, Andrew P Lieberman, Virginia M Lee, John Q Trojanowski, Vivianna M Van Deerlin, Thomas D Bird, Douglas R Galasko, Eliezer Masliah, Charles L White, Juan C Troncoso, Didier Hannequin, Adam L Boxer, Michael D Geschwind, Satish Kumar, Eva-Maria Mandelkow, Zbigniew K Wszolek, Ryan J Uitti, Dennis W Dickson, Jonathan L Haines, Richard Mayeux, Margaret A Pericak-Vance, Lindsay A Farrer, Alzheimer's Disease Genetics Consortium, Owen A Ross, Rosa Rademakers, Gerard D Schellenberg, Bruce L Miller, Eckhard Mandelkow, Daniel H Geschwind
JournalHuman molecular genetics (Hum Mol Genet) Vol. 21 Issue 15 Pg. 3500-12 (Aug 01 2012) ISSN: 1460-2083 [Electronic] England
PMID22556362 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • MAPT protein, human
  • tau Proteins
Topics
  • Aged
  • Alzheimer Disease (epidemiology, genetics)
  • Frontotemporal Dementia (epidemiology, genetics)
  • Genetic Predisposition to Disease
  • Genetic Variation
  • Genotype
  • Haplotypes
  • Humans
  • Middle Aged
  • Risk
  • tau Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: